Get notified of page updates
Education > XRAY > Search Results

FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you. XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program

How To Use XRAY
Search for Articles Submit an Article for Review
41 through 50 of 268

Relevance: High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: People with cancer considering a COVID-19 booster

The National Comprehensive Cancer Network has issued new guidelines for COVID-19 vaccinations. Guidelines now recommend a booster or third dose of the Pfizer-BioNTech or Moderna vaccine for patients with cancer, including those undergoing active treatment. Currently, these updated guidelines do not address people who had the one-dose Johnson & Johnson vaccine. (posted 11/16/2021)

Read More

Relevance: Medium-High

Strength of Science: High

Research Timeline: Human Research

View Related Clinical Trials

Study : Bone-protecting drugs cut the risks for fractures caused by metastatic prostate cancer treatments

Most relevant for: People with metastatic castration resistant prostate cancer

Skeletal problems, especially bone fractures, are common in patients with advanced prostate cancer. To prevent these, many guidelines recommend the use of bone-protecting agents during treatment. The importance of giving a bone-protecting agent when treating patients with metastatic castration-resistant prostate cancer and bone metastases was confirmed in early results of an ongoing phase III trial. (11/5/21)

Read More

Relevance: High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Study : Genetic testing for inherited mutations may be helpful for all people with advanced or metastatic cancer

Most relevant for: people with metastatic or recurrent cancer

In a study of nearly 12,000 cancer patients with a variety of cancers, eight percent of participants with metastatic cancer had an inherited mutation in a cancer gene that qualified them for a targeted treatment approved by the FDA or for participation in a clinical trial. The majority of people with metastatic cancer were unaware that they had an inherited mutation, and had not receive gene-directed treatment to which their tumor may have responded. The study authors suggest that genetic testing for inherited mutations may be warranted for all patients with advanced or metastatic cancer. (posted 9/30/21)

Este artículo está disponible en español.

Read More

Relevance: Medium-Low

Research Timeline: Human Research

View Related Clinical Trials

Update : Blood tests called liquid biopsies for cancer screening, monitoring and treatment

Most relevant for: People considering a liquid biopsy to screen for cancer

Could a simple blood test change cancer detection, treatment and monitoring? Several companies are offering a type of blood test known as a liquid biopsy to detect multiple cancers at their earliest stages, monitor response to treatment and help choose the best treatment. Although progress has been made using liquid biopsies to treat cancer, these tests have not yet been shown to detect cancer early enough to save lives. (posted 9/29/21)

Este artículo está disponible en español.

Read More

Relevance: Medium

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Study : Do sugared beverages increase the risk of early-onset colorectal cancer?

Most relevant for: Healthy people with an average colorectal cancer risk

A study of female nurses in the U.S. suggests that a high intake of sugar-sweetened beverages may increase the risk of colorectal cancer before age 50. However, researchers saw few early-onset colorectal cancer cases which limited the findings. (posted 9/21/21)

Read More

Relevance: Medium-High

Quality of Writing: High

View Related Clinical Trials

Article : Transgender peoples' perspectives of being diagnosed with gender-associated cancer

Most relevant for: transgender people

An ABC News article provides viewpoints and data that conveys the added stress experienced by transgender and gender-nonconforming people when they are diagnosed with gender-associated cancer (e.g., ovarian or prostate cancer) that does not match their gender identity. (posted 9/13/21)

Este artículo está disponible en español.

Read More

Relevance: Medium-High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Update : Pembrolizumab receives FDA approval for people with early-stage, triple-negative breast cancer

Most relevant for: People with early-stage, triple-negative breast cancer who have a high risk for recurrence

The FDA approved the immunotherapy drug pembrolizumab (Keytruda) for the treatment of early-stage triple-negative breast cancer that has a high risk for recurrence.  This marks the first approval for this type of drug, known as an immune checkpoint inhibitor, for the treatment of early-stage breast cancer. (posted 9/2/21)

Este artículo está disponible en español.

Read More

Relevance: High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Study : Drinking coffee or tea may improve survival after breast cancer

Most relevant for: Women with breast cancer who drink coffee or tea.

In a study of 8,900 women with stage 1, 2 or 3 breast cancer, those who drank coffee survived longer after a breast cancer diagnosis than those who did not drink coffee. Both coffee and tea were linked to improved survival from any cause. Several factors were linked to greater coffee or tea consumption, so this finding must be taken with some caution. However, breast cancer survivors who are regular coffee or tea drinkers may find this research reassuring.  (posted 8/31/21)

Este artículo está disponible en español.

Read More

Relevance: High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Study : Frequency of inherited mutations linked to breast cancer are similar in Black and white women

Most relevant for: Non-Hispanic Black and white women with breast cancer

The CARRIERS study looked at the rate of inherited mutations in women with and without breast cancer. In an extension of the CARRIERS study, researchers found no difference in the frequency of inherited mutations in breast cancer genes among Black and white women with breast cancer. A few individual genes differed in frequency: BRCA2 and PALB2 mutations were seen more often in Black women, while CHEK2 mutations were seen less often. Researchers concluded that race should not be used to determine who is referred for genetic testing. (posted 8/13/21)

Read More

Relevance: Medium-High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Guideline : ASCO guidelines recommend olaparib for people with early-stage, high-risk breast cancer and an inherited BRCA mutation

Most relevant for: People with early-stage HER2-negative breast cancer and an inherited BRCA mutation

The American Society of Clinical Oncology (ASCO) has updated their breast cancer treatment guidelines to include treatment with the PARP inhibitor olaparib (Lynparza) for one year after completing chemotherapy, surgery and radiation (if used) to improve outcomes of people with an inherited mutation in BRCA1 or BRCA2 with early-stage, HER2-negative breast cancer who have a high risk for recurrence. (posted 8/6/21) Update: Based on results from the OlympiA Study, the FDA approved olaparib as adjuvant treatment for people with an inherited BRCA mutation who have been diagnosed with early-stage HER2-negative breast cancer and are at high risk for recurrence. (03/11/2022)

Este artículo está disponible en español.

Read More